You are viewing the site in preview mode

Skip to main content

Advertisement

Table 4 Results of regression analysis of processeda quarterly health costs in first two years after baseline (N = 2059)

From: Telemedical monitoring of patients with chronic heart failure has a positive effect on total health costs

  Reference Estimate CI 95% p-value
2.5% 97.5%
Study group Control group −298.58 − 1312.13 714.97 0.5635
Residential area (Berlin vs rural) Rural 262.69 − 101.60 626.98 0.1575
Interaction: Group x Residential area 407.35 407.35 1493.06 0.4619
Age group
 46–50 years 41–45 years 2832.23 − 782.80 6447.27 0.1246
 51–55 years 41–45 years 2875.11 −606.67 6356.89 0.1055
 56–60 years 41–45 years 2600.31 −823.07 6023.69 0.1365
 61–65 years 41–45 years 2569.53 −820.65 5959.71 0.1373
 66–70 years 41–45 years 2840.77 − 533.57 6215.11 0.0989
 71–75 years 41–45 years 3259.24 − 109.66 6628.14 0.0579
 76–80 years 41–45 years 3318.69 − 50.93 6688.32 0.0536
 81–85 years 41–45 years 3017.17 −356.79 6391.14 0.0796
 86–90 years 41–45 years 2919.52 − 469.23 6308.27 0.0913
 91–95 years 41–45 years 2870.68 − 689.65 6431.00 0.1140
Sex Male −96.52 − 369.46 176.42 0.4881
NYHA class
NYHA II NYHA I 314.97 −757.31 1387.24 0.5646
NYHA III NYHA I 375.11 − 696.74 1446.96 0.4926
NYHA IV NYHA I 776.31 −302.57 1855.18 0.1584
 Hospitalizations related to CHF (continuous) −27.61 − 195.63 140.40 0.7472
 Baseline health costs (continuous) 0.34 0.29 0.39 < 0.0001***
Intake of medication related to CHF (yes / no by groups of agents)
 Angiotensin-converting enzyme no −251.08 − 520.92 18.76 0.0682
 Beta-blocker no − 470.81 − 741.91 −199.71 0.0007***
 Renin-inhibitors no −283.79 − 1553.61 986.03 0.6612
 Cardiac glycosides no 97.57 − 252.61 447.75 0.5848
 Diuretics no 533.86 247.94 819.78 0.0003***
 AT1 receptor blocker no −140.25 −491.33 210.83 0.4335
Mental and behavioral disorders (yes / no by blocks of ICD-10 Chapter V)
 F00 – F09 (Organic, including symptomatic, mental disorders) no 386.31 −87.09 859.70 0.1097
 F10 – F19 (Mental and behavioral disorders due to psychoactive substance use) no −83.55 − 544.49 377.39 0.7223
 F20 – F29 (Schizophrenia, schizotypal and delusional disorders) no − 288.83 − 1375.19 797.53 0.6021
 F30 – F39 (Mood [affective] disorders) no 30.78 − 326.67 388.23 0.8659
 F40 – F49 (Neurotic, stress-related and somatoform disorders) no 11.66 − 351.60 374.92 0.9498
 F50 – F59 (Behavioral syndromes associated with physiological disturbances and physical factors) no −86.95 − 775.45 601.54 0.8044
 F60 – F69 (Disorders of adult personality and behavior) no 816.43 − 367.37 2000.23 0.1764
 F70 – F79 (Mental retardation) no 291.70 − 2155.13 2738.54 0.8152
 F80 – F89 (Disorders of psychological development) no
 F90 – F98 (Behavioral and emotional disorders with onset usually occurring in childhood and adolescence) no −340.42 − 2933.64 2252.80 0.7969
 F99 – F99 (Unspecified mental disorders) no 5878.45 − 562.31 12,319.21 0.0736
Intercept − 1689.37 − 5226.05 1847.32 0.3490
  1. aHealth costs after performing the excluding-and-capping algorithm, Significance codes: ***p < 0.001, **p < 0.01, *p < 0.05